Skip to main content

Table 1 Overview of FAO roles in cancer therapy

From: Fatty acid oxidation: driver of lymph node metastasis

FAO targeting drug

Clinical application

Cancer type

Mechanism of action

References

Metformin

Medicine for type 2 diabetes

Breast cancer

Inhibiting FAO at clinical doses

[117]

Etomoxir

Retired from phase II clinical trial for diabetes and heart failures

Bladder cancer

Suppressing tumor progression and inducing cell cycle arrest via PPARγ-mediated pathway

[118]

Malignant glioma

Targeting FAO to reduce energy production and cellular proliferation in glioma cells

[119]

Leukemia

Decreasing leukemia cells proliferation and sensitizing leukemia cells to apoptosis induced by ABT-737 and Nutlin 3a

[120]

Peritoneal metastatic colorectal cancer

Inhibiting cancer-associated fibroblast FAO to decline colorectal cancer metastasis

[121]

Epithelial-derived high-grade serous ovarian cancer

Targeting FAO to promote anoikis and inhibit ovarian cancer progression

[37]

Nasopharyngeal carcinoma

Targeting FAO to sensitize cancer to radiation therapy

[115]

Ranolazine

Medicine for angina pectoris in Europe and United States

Leukemia

Decreasing leukemia cells proliferation and sensitizing leukemia cells to apoptosis induced by ABT-737 and Nutlin 3a

[120]

Perhexiline

Medicine for angina pectoris in Australia and Asia

Leukemia

Targeting CPT to eliminate chronic lymphocytic leukemia cells in stromal microenvironment

[122]